Program
Zirconium Zr 89 Girentuximab
Also written as “89Zr-TLX250 PET/CT” and “89Zr-Girentuximab”.
Its studies are mostly in Carcinoma, Renal Cell, led by Telix Pharmaceuticals.
Drug pageZirconium Zr 89 Girentuximab: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 3, since Nov 26, 20242 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Telix Pharmaceuticals | 21 open or running | phase 3since Nov 26, 2024 | Apr 5, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 5, 2023First study: phase 1 study in Carcinoma, Renal CellFirst studyNCT05861778 · 10 enrolled · China
- Nov 26, 2024Phase 3 study in Carcinoma, Renal CellNCT06750419 · 82 planned · China
TargetBeta
CA9 →read by rule
“A radioimmunoconjugate comprised of the recombinant chimeric monoclonal antibody girentuximab, that binds an extracellular epitope of carbonic anhydrase IX (CAIX), and ”NCIt, by rule
Other programs on CA9
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sulthiamerule | Shionogi | phase 2 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06750419Carcinoma, Renal Cell · China | 3 | Recruiting | Jun 30, 2026 | 82 |
| NCT05861778Carcinoma, Renal Cell · China | 1 | Completed | Nov 27, 2023 | 10 |
How it is read
Names in the registry
- “89Zr-TLX250 PET/CT”, 1 entry
- “89Zr-Girentuximab”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Renal Cell, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.